Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

322 ARTÍCULOS , VIENDO DEL 241 AL 255

Neurochemical basis for symptomatic treatment of Alzheimer's disease

Francis PT, Ramírez MJ, Lai MK.

Neuropharmacology. 2010 Sep-Oct;59(4-5):221-9. doi: 10.1016/j.neuropharm.2010.02.010. Epub 2010 Feb 13.

[Institutionalization of mentally ill in old age]

Riedel-Heller SG, Luppa M, König HH.

Psychiatr Prax. 2010 Mar;37(2):53-5. doi: 10.1055/s-0029-1223514. Epub 2010 Feb 24.

Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease

Cumbo E, Ligori LD.

Epilepsy Behav. 2010 Apr;17(4):461-6. doi: 10.1016/j.yebeh.2010.01.015. Epub 2010 Feb 25.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

Non-pharmacologic management of sleep disturbance in Alzheimer's disease

David R, Zeitzer J, Friedman L, Noda A, O'Hara R, Robert P, Yesavage JA.

J Nutr Health Aging. 2010 Mar;14(3):203-6. doi: 10.1007/s12603-010-0050-9.

Clinical trial efforts in Alzheimer disease: why test statins?

Arvanitakis Z, Knopman DS.

Neurology. 2010 Mar 23;74(12):945-6. doi: 10.1212/WNL.0b013e3181d6479a. Epub 2010 Mar 3.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes

Weintraub D, Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group.

Am J Geriatr Psychiatry. 2010 Apr;18(4):332-40. doi: 10.1097/JGP.0b013e3181cc0333.

Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence

Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W.

Drugs. 2010 Mar 26;70(5):513-28. doi: 10.2165/11533070-000000000-00000.

Apple juice improved behavioral but not cognitive symptoms in moderate-to-late stage Alzheimer's disease in an open-label pilot study

Remington R, Chan A, Lepore A, Kotlya E, Shea TB.

Am J Alzheimers Dis Other Demen. 2010 Jun;25(4):367-71. doi: 10.1177/1533317510363470. Epub 2010 Mar 25.

[Premature immunosenescence: a pathogenetic factor in Alzheimer's disease?]

Richartz-Salzburger E, Stransky E, Laske C, Köhler N.

Nervenarzt. 2010 Jul;81(7):837-43. doi: 10.1007/s00115-009-2918-7.

Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics

Duce JA, Bush AI.

Prog Neurobiol. 2010 Sep;92(1):1-18. doi: 10.1016/j.pneurobio.2010.04.003. Epub 2010 May 2.

ECT treatment for two cases of dementia-related aggressive behavior

Wu Q, Prentice G, Campbell JJ.

J Neuropsychiatry Clin Neurosci. 2010 Spring;22(2):E10-11. doi: 10.1176/jnp.2010.22.2.247.e10.

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis

Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X.

Dement Geriatr Cogn Disord. 2010;29(5):406-12. doi: 10.1159/000296073. Epub 2010 May 21.

["Syndrome de glissement": clinical description, psychopathological models, and care management]

Weimann Péru N, Pellerin J.

Encephale. 2010 Jun;36 Suppl 2:D1-6. doi: 10.1016/j.encep.2008.08.006. Epub 2009 Apr 22.

[Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences]

Nieoullon A.

Psychol Neuropsychiatr Vieil. 2010 Jun;8(2):123-31. doi: 10.1684/pnv.2010.0208.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias